Auranofin modulates gelatinase release from rat neutrophils.
We have examined the effects of auranofin and some nonsteroidal anti-inflammatory drugs (NSAID) on the release of gelatinase from rat neutrophils. Two preparations of neutrophils were used, one derived from normal blood and the other from the inflamed pleural fluids of carrageenin-elicited pleurisy. Both neutrophil preparations released gelatinase in response to stimulation by serum-treated zymosan (STZ) or concanavalin A (Con A). Control, blood-derived neutrophils exposed to STZ produced more than a four-fold increase in the release of gelatinase, a response significantly inhibited by the presence of auranofin at 10(-5) and 10(-4) M. Inflamed, pleural neutrophils exposed to STZ produced a doubling in gelatinase release and this was also inhibited by auranofin at 10(-5) and 10(-4) M. The release of gelatinase by control neutrophils (no stimulation) or by neutrophils exposed to Con A was enhanced by 10(-6) M auranofin. In contrast, the NSAIDs aspirin, piroxicam, sulindac, indomethacin and naproxen had no inhibitory action on neutrophil gelatinase release. We conclude that auranofin is an effective inhibitor of gelatinase release from neutrophils and this property may represent a contributory factor assigned to the beneficial therapeutic action of gold salts.
Sopata
I
I
Department of Biochemistry, Institute of Rheumatology, Warsaw, Poland.
Wojtecka-Lukasik
E
E
Maśliński
S
S
D000818:Animals; D001310:Auranofin / Q000494:pharmacology*; D003208:Concanavalin A / Q000494:pharmacology; D018093:Gelatinases; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D010434:Pepsin A / Q000378:metabolism*; D051381:Rats; D015054:Zymosan / Q000494:pharmacology
D003208:Concanavalin A; D001310:Auranofin; D015054:Zymosan; D010434:Pepsin A; D018093:Gelatinases